Medicus Pharma Says CD228V ADC Now Principal Strategic Priority, With Initial Development In Relapsed Or Refractory Melanoma; Says FDA Authorized Initiation Of Registrational Phase 2b SkinJect Study In Gorlin Syndrome
Share
Why It Matters
Medicus Pharma is focusing on a new medicine called CD228V and got permission to start an important study testing it. This shows the company believes in this drug and is moving forward with a big step in development.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.